Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy
Authors:
- Alyssa M. DuffyADAlyssa M. Duffy
- Anshika GoenkaAGAnshika Goenka
- Maryam I. AzeemMAMaryam I. Azeem
- Azmain TazATAzmain Taz
- Sayalee V. PotdarSPSayalee V. Potdar
- Sara A. ScottSSSara A. Scott
- Ellen MarinEMEllen Marin
- Jonathan L. KaufmanJKJonathan L. Kaufman
- Craig C. HofmeisterCHCraig C. Hofmeister
- Nisha S. JosephNJNisha S. Joseph
- Vikas A. GuptaVGVikas A. Gupta
- Sagar LonialSLSagar Lonial
Open Access
- 31 July 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (CA238471, AR077926, CA197603)
- Leukemia and Lymphoma Society (SCOR)
- Paula and Rodger Riney Foundation (Myeloma award)
This publication has 3 references indexed in Scilit:
- Current use of bispecific antibodies to treat multiple myelomaHematology-American Society Hematology Education Program, 2023
- Teclistamab in Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2022
- Bispecific Antibodies in Multiple Myeloma: Present and FutureBlood Cancer Discovery, 2021